AI Article Synopsis
- The researchers created a new recombinant protein called DsbA-F/M2:81-95 to enhance immune responses against respiratory syncytial virus (RSV) in mice by combining a carrier protein with a viral epitope.
- This new protein not only stimulates effective virus-specific cytotoxic T lymphocyte (CTL) responses but also provides protective immunity without worsening the disease.
- Additionally, DsbA-F/M2:81-95 significantly prolongs CTL responses in vivo by nearly three times compared to the viral epitope alone, suggesting its potential as a safe and effective candidate for RSV vaccine development.
Article Abstract
In an effort to seek a means of inducing long lasting respiratory syncytial virus-specific CTL responses in mice, we constructed a new recombinant protein, DsbA-F/M2:81-95, by fusing carrier protein DsbA (disulfide bond isomerase) to the N-terminus of CTL chimeric epitope F/M2:81-95 of this virus. DsbA-F/M2:81-95 can induce effectively virus-specific CTL responses as well as protective immunity without association with enhanced disease. Furthermore, compared with F/M2:81-95 alone, it increases the longevity of CTL responses in vivo up to 2.93 folds. Our study emphasizes that appropriate stimulation of non-antigen-specific T helper cells is essential to induce long lasting CD8+ CTL, and also implies DsbA-F/M2:81-95 may be a promising candidate for RSV vaccine development since it is an efficacious and safe immunogen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2004.11.066 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!